FeesSafety
Pluang+
Home/News Feed/Denali Therapeutics' AVLAYAH launch drives $7.8M revenue with strong patient and payer support
DNLI
$18.74
-$0.15 -0.79%

Denali Therapeutics' AVLAYAH launch drives $7.8M revenue with strong patient and payer support

Market News
14 Nov 2026, 03:08 WIB
Seeking Alpha
View Source
Bullish
Denali Therapeutics' AVLAYAH launch drives $7.8M revenue with strong patient and payer support

Denali Therapeutics reported a strong launch for its drug AVLAYAH, achieving $7.8 million in commercial revenue just in the second quarter after launch. The drug has gained significant interest from patients, physicians, and payers, with about 70% of commercial lives covered and Medicaid coverage in 20 states. This collaborative support is seen as key to the successful market entry. The company plans to continue advancing its pipeline programs with upcoming data readouts next year.

Denali Therapeutics Inc. (DNLI) shares are trading at USD 18.74 on Pluang, down 0.79% in the last day. As of Nov 14, 2026 08:21 WIB, the stock has a market cap of $3.03 billion and a 52-week range between $16.02 and $27.21.

More News (DNLI)

Denali Therapeutics initiates Buy as Avlayah sales beat expectations and pipeline advances toward 2027 approval.

Denali Therapeutics initiates Buy as Avlayah sales beat expectations and pipeline advances toward 2027 approval.

Denali Therapeutics received a Buy rating following strong Q3 Avlayah sales of $17.8M, surpassing guidance, with Q4 expected to grow over 65%. The company’s DNL126 drug for Sanfilippo A is on track for accelerated approval in 2027, leveraging a prove...

Analyst Insights
Bullish
16 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App